Literature DB >> 20194843

Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.

Pierre Laneuville, Clifford Dilea, Ophelia Q P Yin, Richard C Woodman, Jürgen Mestan, Paul W Manley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20194843     DOI： 10.1200/JCO.2009.26.4945

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  19 in total

Review 1.  Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations.

Authors:  Jing Ai; Ramon V Tiu
Journal:  Ther Adv Hematol       Date:  2014-08

2.  [Modern therapy of chronic myeloid leukemia: an example for paradigma shift in hemato-oncology].

Authors:  A A Leitner; R Hehlmann
Journal:  Internist (Berl)       Date:  2011-02       Impact factor: 0.743

Review 3.  Selection of therapy: rational decisions based on molecular events.

Authors:  Jamshid S Khorashad; Michael W N Deininger
Journal:  Hematol Oncol Clin North Am       Date:  2011-10       Impact factor: 3.722

Review 4.  Chronic myeloid leukemia: mechanisms of resistance and treatment.

Authors:  Elias Jabbour; Sameer A Parikh; Hagop Kantarjian; Jorge Cortes
Journal:  Hematol Oncol Clin North Am       Date:  2011-10-19       Impact factor: 3.722

5.  Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib.

Authors:  Golale Rostami; Mohammad Hamid; Majid Yaran; Mohsen Khani; Morteza Karimipoor
Journal:  J Hum Genet       Date:  2015-03-05       Impact factor: 3.172

Review 6.  Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.

Authors:  Elias J Jabbour; Timothy P Hughes; Jorge E Cortés; Hagop M Kantarjian; Andreas Hochhaus
Journal:  Leuk Lymphoma       Date:  2013-11-12

Review 7.  Development of an effective therapy for chronic myelogenous leukemia.

Authors:  David W Woessner; Carol S Lim; Michael W Deininger
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

8.  Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.

Authors:  Elias Jabbour; Jorge Cortes; Fabio P S Santos; Dan Jones; Susan O'Brien; Gabriela Rondon; Uday Popat; Sergio Giralt; Partow Kebriaei; Roy B Jones; Hagop Kantarjian; Richard Champlin; Marcos de Lima
Journal:  Blood       Date:  2010-12-14       Impact factor: 22.113

Review 9.  The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.

Authors:  Oliver Hantschel; Florian Grebien; Giulio Superti-Furga
Journal:  Cancer Res       Date:  2012-09-21       Impact factor: 12.701

Review 10.  Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.

Authors:  Elias J Jabbour; Jorge E Cortes; Hagop M Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.